New hope for saving failing kidney transplants
NCT ID NCT02201576
Summary
This study tested whether adding the drug bortezomib to standard treatments could help control chronic rejection in kidney transplant patients. The trial involved 60 people whose bodies were attacking their transplanted kidneys with harmful antibodies. Researchers aimed to see if this combination could reduce the damaging antibodies and stabilize the kidney's condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ANTIBODY-MEDIATED TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Necker Enfants-malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.